Aetna, a CVS Health company (NYSE:CVS), announced on Tuesday that it is introducing a generative AI-powered conversational experience in its digital channels designed to simplify healthcare.
This offering will allow members to quickly and easily navigate their benefits for a personalised experience.
The new capability was initially launched to a limited population in October, with access expanding throughout the rest of 2025 and the first half of 2026.
Aetna members will be able to use their device to verbally interact with the assistant with full voice enablement. The assistant will also be embedded within Aetna's recently announced Care Paths feature, a digital experience to help members navigate certain conditions.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval